Resources for Researchers
The ACTG NL consists of Core Laboratory groups in immunology, pharmacology, virology and TB.
The ARLG biorepositories were created to aid in the development and evaluation of novel diagnostic tests and laboratory techniques, study mechanisms of resistance, generate preliminary data for study concepts, and support/mentor early-stage investigators pursuing research in the field of antibact
The National Emerging Infectious Diseases Laboratories (NEIDL) is part of a national network of secure facilities studying infectious diseases that are—or have the potential to become—major public health concerns
The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.
The Tufts New England Regional Biosafety Laboratory (RBL) is one of the NIAID-supported Regional Biocontainment Laboratories.
The University of Tennessee Regional Biocontainment Laboratory (RBL) is one of the NIAID-supported Biocontainment Laboratories.
The Bioinformatics and Computational Biosciences Branch (BCBB) offers a suite of scientific services and resources for the NIAID research community and its collaborators. BCBB provides expertise and computational solutions to researchers at all levels of experience.
The NIAID-funded Bioinformatics Resource Centers provide data-driven, production-level, sustainable computational platforms to enable sharing and access to data, portable computational tools, and standards that support interoperability for the infectious diseases research community.
Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.
GUNK center is part of the NIAID Functional Genomics Program. This center was created to investigate the role of previously uncharacterized genes of A. baumannii in its ability to cause human disease. Three projects have been established to:
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci
The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.
Note: Devices are excluded.
The Gnotobiotic Animal Facility houses purchased experimental mice in experimental isolators that serve as important resources for researchers studying the microbiome. The mice in this facility are germ-free, i.e., born and raised in absence of live microbes.
NIAID’s microbiome sequencing facility studies the structure and function of the microbiome associated with various hosts and body sites. This facility has one dedicated team and is equipped with an Ilumina MiSeq, which can sequence whole genomes or specific amplicons.
The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclo
This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.
The Structural Genomics Centers for Infectious Diseases provide the research community with:
The Systems Biology Consortium for Infectious Diseases is a community of systems biologists who integrate experimental biology, computational tools and modeling across temporal and spatial scales to improve our understanding of infectious disease
The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.
The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).